The research team, led by Yasmine Chemrouk of CHU Orléans and the University of Strasbourg, recruited fifty bereaved spouses from nine hospital sites across France between September 2022 and March 2025, primarily through palliative care units. All participants had lost a partner to cancer after the initiation of palliative care, and all were interviewed three times over the first year of grief. Twenty-two participants completed all three interviews and formed the analytic corpus, yielding sixty-six interviews in total. The interviews, conducted online by two PhD-level clinical psychologists trained in psycho-oncology, averaged between 44 and 81 minutes across the waves and were transcribed verbatim in French.

What makes the study technically distinctive is its method. Rather than relying solely on thematic reading, the team applied ALCESTE—Analyse Lexicale par Contexte d’un Ensemble de Segments de Texte—a corpus-driven lexicometric tool originally developed by Max Reinert in 1979. The software segments transcripts into context units, then uses chi-square statistics to identify co-occurring word patterns, generating lexical classes that represent clusters of meaning within the corpus. Six separate classifications were performed, one for each gender-by-wave sub-corpus, using a double descending hierarchical classification procedure in which only classes stable across two parallel runs were retained. Between 59 and 84 percent of elementary context units were classified in each run. The lexical analysis was then complemented by a codebook, or coding reliability, approach to thematic analysis, in which two analysts coded the most characteristic segments independently, compared results, and resolved disagreements through a third researcher acting as arbiter.

The clearest pattern emerged at the first interview, three months after the death. Both men and women devoted enormous narrative space to the final days and the circumstances of dying—but in contrasting registers. Women’s accounts were sensorially detailed and emotionally embodied: they described breathing patterns, medical devices, physical deterioration, and the urgency of bedside decisions. One woman recalled seeing her husband suffocating and turning off the noise of a machine so she could think. Women also framed the illness within the biography of the couple and the family, making the death part of a longer shared history. Men, by contrast, recounted the same period at greater emotional distance, in a factual register organized around clinical management, logistics, appointments, and prior family losses. One man described being perfectly on top of every detail of his wife’s care, listing the transport and consultations he had managed.

By six months, the dominant lexical classes for both genders were weakly specified—residual categories that the authors treat with caution—but the thematic reading suggested divergent preoccupations. Women’s narratives foregrounded emotional vulnerability, disbelief, intrusive end-of-life memories, and the mental load of maintaining family life: cooking for children because otherwise no one would eat, handing over the deceased’s belongings, keeping promises made to the children. Men more often described the disruption of routines and the relational absence left behind, framing bereavement as a reorganization of daily life rather than a struggle over the circumstances of death. One man spoke of the closeness the couple had still wanted to experience together, a longing anchored in shared habits rather than in the final moments.

At twelve months, the trajectories diverged again. Women tended to approach future planning cautiously, hesitating over the possibility of new relationships out of continuing emotional loyalty to their partner and concern for their children. Men more often re-engaged in social life and personal projects—one described planning a motorcycle trip to the mountains with a different group of friends—and several reflected on palliative sedation in ways that contained guilt, framing sedation as a positive intervention that ensured the absence of suffering. Notably, the researchers also identified contrasting cases: one woman whose narrative was anchored in the factual, clinical register more typical of men, and one man whose account centered on suffering and accompaniment in the register more typical of women. These departures support the authors’ central claim that gendered narrative registers are fluid, overlapping tendencies rather than fixed categories.

Across genders, one factor proved decisive for later grief: the quality of end-of-life communication, particularly around sedation. In France, continuous deep sedation until death is legally framed by the 2016 Claeys–Leonetti law, which grants patients meeting specific end-of-life criteria the right to deep and continuous sedation maintained until death. In the sample, continuous deep sedation was reported by 33.3 percent of the men’s deceased partners and 50 percent of the women’s, with the remainder involving intermittent or light sedation or none at all. The study found that when sedation was clearly explained by healthcare teams, spouses tended to integrate it as a compassionate act; when communication was insufficient, they reported unresolved questions, guilt, and intrusive recollections—sometimes years of replaying whether sedation had shortened a life or relieved its pain. This echoes broader evidence that poorly understood end-of-life decisions can contribute to prolonged grief symptoms.

The study also documented a stark economic dimension of widowhood. Half of the women reported a reduction in household income of at least 50 percent after their loss, and a further 30 percent reported reductions of up to 25 percent, whereas two-thirds of the men reported no financial consequences at all. This disparity aligns with population-level research showing that women face higher risks of financial decline and long-term instability after widowhood, and it underscores the authors’ argument that grief unfolds not only in emotional and relational domains but within structural inequalities that can intensify vulnerability. Bereavement support, they suggest, must therefore address socioeconomic realities alongside psychological ones.

The authors are careful about the limits of their findings. The sample is small and qualitative, so results are framed as transferable to comparable contexts rather than statistically generalizable. Inclusion in the analysis depended on recruitment date and the pace of manual transcription, and the binary operationalization of gender may not capture the diversity of participants’ experiences. Because all interviews were conducted by two female interviewers, a same-gender dyad effect cannot be excluded for the women, though not for the men. Women also gave longer interviews, producing larger sub-corpora, and descending hierarchical classification is sensitive to corpus size—so the authors explicitly describe their results as gendered narrative registers observed within this sample and interview context, not as evidence of fundamentally different grief processes. Quotes were translated from French, and nuances may be lost.

Even with those caveats, the study’s implications are concrete. It suggests that bereavement care should be individualized and gender-sensitive without being stereotyped: that men’s instrumental, task-oriented accounts may conceal emotional ruptures deserving attention, and that women’s embodied, biographical narratives also carry a heavy cognitive load of decision-making and family continuity. It points to clear, early communication about palliative sedation as a modifiable clinical factor with measurable consequences for how grief is integrated over the first year. And it demonstrates, methodologically, that computational lexical analysis and careful thematic coding can be combined to track how the language of loss itself evolves—month by month, from the sensory chaos of the final hours toward the cautious, halting grammar of a life rebuilt.

Subject of Research: Gendered narrative registers in spousal bereavement after cancer-related death in palliative care, including continuous deep sedation until death

Article Title: End-of-life sedation and gendered narrative registers: a longitudinal qualitative study of spouses bereaved by cancer

Article References: Chemrouk, Y., Sani, L., Ducos, M., Gauthier, P., & Bacqué, M.-F. (2026). End-of-life sedation and gendered narrative registers: a longitudinal qualitative study of spouses bereaved by cancer. Supportive Care in Cancer, 34(10), Article 980. https://doi.org/10.1007/s00520-026-11224-6

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11224-6

Keywords: spousal bereavement, palliative care, palliative sedation, cancer, gender differences, grief, qualitative longitudinal study, ALCESTE lexical analysis, end-of-life communication, widowhood, France, narrative registers

The research team, led by Pauline Gesson and Clémence Houizot of Nantes University Hospital together with corresponding author Adrien Evin, examined all patients who underwent continuous deep sedation until death in their palliative care unit between 2020 and 2024. Of 1,376 patients admitted during the study window, 287 received continuous deep sedation with midazolam as the first-line agent. The cohort had a median age of 69 years, with an interquartile range of 59 to 77, and just over half of the patients, 52.3 percent, were male. Cancer was the underlying diagnosis in 74.2 percent of cases, reflecting the typical caseload of a dedicated palliative care unit. The researchers collected demographic, clinical, pharmacological, and organisational data from medical records and then applied univariable and multivariable logistic regression to identify factors associated with what they defined as failure of midazolam monotherapy: the need to introduce additional sedative drugs.

The headline finding is stark. Midazolam monotherapy failed in 211 of the 287 patients, a failure rate of 73.5 percent. In other words, roughly three out of every four patients who entered continuous deep sedation on midazolam alone ultimately required at least one additional sedative to achieve or maintain adequate sedation until death. Escalation most commonly involved chlorpromazine, a first-generation antipsychotic with sedative properties, which was added alone in 134 of the 211 escalated patients, or 63.5 percent. Propofol, a short-acting intravenous anaesthetic agent, was used alone in 20 patients, or 9.5 percent, while both agents were required in 57 patients, or 27 percent. These proportions sketch a practical hierarchy at the bedside: when midazolam is insufficient, French palliative teams reach first for chlorpromazine, reserving propofol, and combinations of the two, for the most resistant cases.

The statistical analysis uncovered several independent determinants of failure, and the most striking of them was polypharmacy. Patients receiving between five and nine concomitant medications had roughly three times the odds of midazolam failure compared with those on fewer drugs, with an odds ratio of 3.06 and a 95 percent confidence interval of 1.60 to 5.91. Remarkably, the risk did not continue to climb with further drug burden: patients on ten or more medications had an almost identical odds ratio of 3.05, with a confidence interval of 1.22 to 8.11. The effect appears to be a threshold phenomenon rather than a dose-response relationship. The authors suggest that the pharmacological milieu created by multiple co-administered drugs, including potential interactions at the level of cytochrome P450 metabolism, protein binding, or receptor dynamics at the GABA-A receptor where midazolam acts, may blunt the drug’s effectiveness in ways that are difficult to predict from any single interaction pair.

The clinical context in which sedation was initiated also mattered profoundly. When continuous deep sedation was performed in the setting of withdrawal of life-sustaining treatment, the odds of midazolam monotherapy failure more than tripled, with an odds ratio of 3.51 and a confidence interval of 1.46 to 9.88. This finding carries particular weight for intensive care and palliative teams who manage the transition when ventilatory support or other organ support is withdrawn. The physiological state of a patient undergoing such withdrawal, including accumulating carbon dioxide, hypoxaemia, agitation, and the pharmacodynamic turbulence of the dying process itself, may create symptom burdens that a benzodiazepine alone cannot reliably control. The result suggests that teams should anticipate the likely need for adjunctive sedation from the outset in these situations rather than treating escalation as an unexpected event.

Perhaps the most scientifically intriguing result concerns age. Rather than treating age as a simple linear variable, the researchers modelled it with restricted cubic splines, a technique that allows the data to reveal non-linear patterns. Age showed a significant non-linear association with sedation failure, with a p-value below 0.001. Although the abstract does not spell out the exact shape of the curve, the very existence of a non-linear effect challenges the common assumption that older patients are uniformly more sensitive to sedatives and therefore easier to sedate. End-of-life pharmacology is shaped by shifting volumes of distribution, changing albumin levels, altered hepatic blood flow, renal decline, and receptor sensitivity changes that do not map neatly onto chronological age. The finding underscores that dosing strategies anchored solely on age-based rules risk being wrong in both directions across the lifespan.

One factor moved in the opposite direction. Patients who had been receiving oxygen therapy in the 24 hours preceding the induction of sedation had a substantially reduced risk of midazolam failure, with an odds ratio of 0.35 and a confidence interval of 0.18 to 0.65. The authors do not over-interpret this protective association, and it may well reflect confounding by indication: patients already on oxygen may represent a different physiological subgroup, or the oxygen may itself alleviate distressing dyspnoea that would otherwise compete with sedation. Nevertheless, the signal is strong enough to warrant attention, and it hints that pre-sedation respiratory status and symptom control in the final day of life may shape how the patient responds to sedative drugs.

The sheer frequency of escalation documented in this single-centre cohort raises questions about whether midazolam monotherapy should remain the default expectation in guidelines and in clinical practice. The authors are careful in their framing: the findings do not argue against midazolam as first-line therapy, which remains supported by its favourable pharmacokinetic profile, titratability, and extensive clinical experience. Instead, they argue for individualised sedation strategies and for early anticipation of combination therapy in patients who carry the identified risk factors. In practical terms, a patient on multiple medications, or a patient whose sedation accompanies the withdrawal of life-sustaining treatment, might benefit from a plan that pre-specifies the dose and timing of an adjunctive agent such as chlorpromazine, rather than leaving the team to improvise an escalation in the middle of the night.

The study’s limitations are those inherent to its design. It was retrospective and conducted at a single palliative care unit, which means the results reflect the protocols, patient mix, and escalation habits of one French university hospital team. The definition of failure, the need for second- or third-line agents, is operational rather than physiological, and it captures both true pharmacological resistance and clinician prescribing behaviour. With 287 sedation episodes, the confidence intervals around some estimates, particularly for the highest polypharmacy category, are wide. Still, the internal consistency of the findings, the use of spline modelling for age, and the adjustment for multiple variables in the multivariable analysis give the results credibility, and the near-universal relevance of the clinical scenario makes external validation studies an obvious next step.

For the growing number of countries legislating or debating continuous deep sedation at the end of life, from France with its Claeys-Leonetti framework to jurisdictions across Europe and beyond, this study delivers a sobering empirical message. The most widely used sedative in the world fails as a single agent in nearly three quarters of the patients to whom it is given for this purpose, and the failure is not random. It clusters around measurable, identifiable characteristics: the burden of concurrent medications, the circumstances of treatment withdrawal, the patient’s position in a complex age-related pharmacological landscape, and the respiratory interventions of the final day. Translating that knowledge into anticipatory prescribing protocols could spare dying patients the distress of inadequate sedation and spare their families the sight of it, while giving clinicians a firmer evidence base for one of medicine’s most delicate decisions.

Subject of Research: Determinants of failure of midazolam monotherapy during continuous deep sedation until death in palliative care

Article Title: Determinants of failure of midazolam monotherapy during continuous deep sedation until death: evidence from a French cohort in a palliative care unit

Article References: Gesson, P., Houizot, C., Coudol, S., Huon, J.-F., Nguyen, O., Prampart‐Fauvet, S., & Evin, A. (2026). Determinants of failure of midazolam monotherapy during continuous deep sedation until death: evidence from a French cohort in a palliative care unit. BMC Medicine. https://doi.org/10.1186/s12916-026-05282-0

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05282-0

Keywords: continuous deep sedation, palliative sedation, midazolam, chlorpromazine, propofol, treatment failure, end-of-life care, polypharmacy, drug interactions, palliative care, refractory symptoms, BMC Medicine